Investigator Initiated Clinical Trials Award. "Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C"

Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C

Awarded By

  • Merck

Contributors

Amount

  • $200,000.00

Start/End

  • 2012 - 2018